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The antisecretory effects of somatostatin (SRIH) and its analogs are widely recognized and provide the
basis for treatment of hormonal hypersecretion in patients with pituitary adenomas, especially in the
settings of acromegaly. Dopamine (DA) agonists have also been used for medical treatment of prolactin
and/or GH hypersecretion, and recent evidence points to an even greater antisecretory effect for a
chimeric molecule, having high affinity for both SRIH and DA receptors. Evidence for an
antiproliferative effect of these compounds has also been provided. This review focuses on the
antiproliferative effects of SRIH and its analogs, of DA and chimeric compounds on pituitary adenomas,
and on the clinical consequences on tumor volume of pharmacological treatment of pituitary
adenomas with these drugs.
European Journal of Endocrinology 156 S29–S35Since the discovery of the antisecretory properties of
somatostatin (SRIH) analogs, these compounds have
been widely employed in the medical therapy of
pituitary adenomas. The natural peptide, SRIH, is
secreted by hypothalamic neurons into the hypophyseal
portal circulation and regulates pituitary hormone
secretion (1). It inhibits growth hormone (GH) and
thyroid-stimulating hormone secretion (2), and also
prolactin (PRL) and adrenocorticotropic hormone
(ACTH) secretion under some circumstances (3). SRIH
transduces its inhibitory effects by interacting with five
different somatostatin receptor (SSTR) subtypes, in
normal pituitary cells as well as in pituitary adenomas
(4). The evidence that SRIH and its analogs have
antisecretory effects prompted many studies aimed at
investigating the possible antiproliferative effects of
these compounds on pituitary adenomas. Indeed, it
has been demonstrated that native SRIH inhibits the
proliferation of both normal and neoplasic cells by
inducing cell cycle arrest or apoptosis, depending on the
receptor subtype and the target tissue (5–7). As a
consequence, many studies have been performed and
octreotide, one of the first SRIH analogs being
synthesized and used in clinical practice, has been
demonstrated to significantly reduce not only PRL
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n Journal of Endocrinologycell line (8). Moreover, in these settings, evidence for
desensitization was shown due to loss of SSTR
expression, which was restored by withdrawal from
long-term exposure to octreotide. In addition, a
dissociation between antiproliferative effects of octreo-
tide, being apparent when SSTRs are highly expressed,
and antisecretory effects, appearing for much lower
SSTR expression levels in the same rat prolactinoma cell
line, was suggested (9). Therefore, many studies
subsequently explored SSTR subtype expression in
pituitary adenomas, demonstrating that SSTR2 is the
most frequently expressed receptor (10). These studies
provided the basis for the use of SRIH analogs in the
medical therapy of pituitary adenomas, in the attempt
to restrain pituitary tumor growth and function.
Evidence for octreotide’s directly antiproliferative effects
was provided by a multicenter randomized trial
recruiting 32 acromegalic patients with pituitary
macroadenoma. A group of 16 patients underwent
octreotide treatment for 4 months before surgical
resection, showing a 83% reduction in the mean
growth fraction in comparison with the untreated
surgical controls (11), indicating that octreotide
pretreatment significantly suppressed pituitary ade-
noma cell growth. In addition, another study showed
that apoptosis was not significantly altered by the
octreotide pretreatment (12), suggesting that a
reduction in cell cycling, rather than an increase in
apoptotic rate, is the basis for the antiproliferative action
of octreotide in somatotrope adenomas. This evidence
was further confirmed by a clinical study where 14
acromegalic patients underwent a 3-monthDOI: 10.1530/eje.1.02352
Online version via www.eje-online.org
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prominent regressive changes and increased perivas-
cular fibrosis when compared with 17 surgical controls.
Moreover, the Ki-67 labeling index was lower in treated
than in untreated patients, supporting the hypothesis
that SRIH analogs have antiproliferative effects on
somatotrope adenomas (13). These effects, however,
are not mirrored by significant morphological changes,
since octreotide pretreatment does not cause necrosis,
whereas it induces acidophilia and interstitial fibrosis,
with a slight reduction in cell size (14). This picture
greatly differs from that observed in prolactinomas after
treatment with a dopamine (DA) agonist, where marked
reduction in cellular, cytoplasmic and nuclear volume
as well as marked perivascular and interstitial fibrosis
and effects on the endoplasmic reticulum and Golgi
have been observed (15). A recent review summarized
the results of SRIH analog treatment on the size of
pituitary adenomas in 921 acromegalic patients (16),
showing that 42% of the patients displayed a reduction
in tumor volume. This effect was more evident in
patients in primary therapy (52%), when compared
with patients who had already undergone surgery
(21%). In addition, only 5% of the patients experienced
further tumor enlargement, suggesting that treatment
with SRIH analogs may contribute to the control of
tumor growth in the majority of patients, at least for the
treatment periods of up to 3 years.
The in vivo antiproliferative effects of octreotide are in
agreement with previous in vitro studies, showing a
significant reduction in cell number in three out of six
primary cultures from GH-secreting pituitary adenomas
exposed for 3 days to 1–10 mM octreotide (17). Similar
effects were shown in primary cultures from clinically
nonfunctioning pituitary adenomas (NFA), where
significant inhibition of cell number was obtained for
higher octreotide concentrations (10 mM), suggesting a
lower SSTR expression level in these pituitary tumors
(17). More insights into the antiproliferative effects of
SRIH and its analogs have been provided by a more
recent study analyzing 15 GH-secreting pituitary
adenomas. SSTR2 and SSTR5 mRNAs were expressed
in all tumors, while SSTR1 and SSTR3 mRNAs were
expressed in 11 and 12 tumors respectively. Primary
cultures were performed and tested with 1 mM SRIH or
lanreotide (Lan), a SRIH analog interacting with both
SSTR2 and SSTR5. After 24 h, no effect was observed in
some cultures, but in others (as well as in the GH3 rat
cell line) a parallel reduction in cell viability and DNA
synthesis was observed. Moreover, tumors that were
responsive to SSTR2- and SSTR5-specific analogs were
also responsive to Lan. This study also highlighted a
dissociation between the in vitro effects of SRIH analogs
on tumor cell proliferation and GH secretion, suggesting
that the inhibition of cell proliferation occurs indepen-
dently of the effects on GH secretion (18).
The mechanism by which SRIH inhibits pituitary cell
proliferation has been investigated in the GH3 ratwww.eje-online.orgpituitary cell line, where octreotide and a chimeric
compound, formed by GH-releasing peptide linked to
SRIH, significantly inhibited cell proliferation by
activating protein tyrosine phosphatases (PTP), invol-
ving a cGMP-dependent pathway (19). The involvement
of PTPs was then confirmed by further studies
performed in GH-secreting pituitary adenoma primary
cultures, where SRIH and Lan inhibited cell prolifer-
ation induced by phorbol esters (PMA). This inhibitory
effect was blocked by incubation with vanadate, a
nonspecific PTP inhibitor, suggesting that this enzyme
family is involved in mediating the antiproliferative
effects of SRIH and its analogs. Moreover, this study
showed that the inhibition of GH secretion was
mediated by blockade of calcium channels and adenylyl
cyclase activity, further supporting the hypothesis that
the inhibition of cell proliferation occurs independently
of the effects on GH-secretory pathways (20). It has been
recently demonstrated that octreotide can induce a
dose-dependent increase in caspase-3 activity, indicat-
ing that this compound can promote apoptosis in
somatotrope tumors. A similar effect was also observed
after treatment with a selective SSTR2 agonist, BIM-
23120, which induces apoptosis by a phosphatase-
dependent mechanism and causes growth arrest by an
increase in p27 and a decrease in cyclin D1 expression
(21). This finding confirmed the previous studies by
Luciani et al. (22), showing that octreotide treatment
induces apoptosis in GH-secreting adenomas, where the
expression level of the antiapoptotic gene seladin-1 is
significantly lower when compared with NFA. In
addition, SRIH analogs have been shown to produce
their antiproliferative action by acting on the PI3K/Akt
signaling pathway and increasing Zac1 gene expression.
Zac1 induces cell cycle arrest and apoptosis and is
highly expressed in normal pituitary, mammary and
ovarian glands but is downregulated in pituitary, breast
and ovarian tumors, suggesting that it might act as an
oncosuppressor gene (23).
Previous studies demonstrated SSTR expression in a
group of NFA, where SRIH and Lan inhibited PMA-
stimulated cell proliferation in most NFA primary
cultures. This effect was once again blocked by vanadate
incubation, providing further evidence for PTP involve-
ment in SRIH signal transduction in pituitary adenomas
(24). Indeed, PTPs are listed among the pathways
activated by SSTRs triggering cell proliferation inhi-
bition, since the phosphatase family, and especially
SHP-1, is involved in the control of apoptosis and in cell
cycle regulation (25). We have previously demonstrated
that constitutive SHP-1 activity controls cell prolifer-
ation in a humanmedullary thyroid carcinoma cell line,
providing also evidence that, upon SSTR2 activation,
SHP-1 activity can be further upregulated leading to cell
proliferation inhibition, despite constitutive activation
of potent proliferative stimuli (26). Taken together, these
results not only confirm that SSTR2 is important in
transducing the antiproliferative signals of SRIH, but






Renner (1994) (17) Acromegaly 6 1–10 mM octreotide Reduction in cell number in three
cultures
Danila (2001) (18) Acromegaly 15 SRIH-, Lan-, SSTR2-, and
SSTR5-selective agonists at
1 mM
Proliferation reduction of 5–60% in
15–40% of the cases
Florio (2003) (20) Acromegaly 13 SRIH, Lan at 1 mM Reduction in PMA-induced cell
proliferation in ten adenomas by
50–70%
Zatelli (2003) (29) Acromegaly 15 SRIH- and a SSTR1-selective
agonists at 10 nM
Reduction in cell viability by 17.5–20%
Renner (1994) (17) NFA 13 Octreotide at 1–10 mM Reduction in cell number in six cultures
Florio (1999) (24) NFA 23 SRIH and Lan at 1 mM Variable inhibition of PMA-induced cell
proliferation
Renner (1994) (17) NFA 13 Bromocriptine
1 mM 15–29% cell number reduction
10 mM 13–43% cell number reduction
Zatelli (2004) (31) NFA 12 SRIH- and a SSTR1-selective
agonists at 10 nM
Reduction in cell viability by 17.5–20%
Gruszka (2006) (62) NFA 10 SSTR/DA chimera 24% cell viability reduction
Bromocriptine 41% cell viability reduction
Sarkar (2005) (46) Rat pituitaries Bromocriptine 1 mM Reduction in proliferating lactotrope
by 10%
Ferrante (2006) (21) Acromegaly 8 Octreotide 10 nM 160% increase in caspase-3 activity
Octreotide 0.1 nM 172% increase in cleaved cytokeratin
18
Luciani (2005) (22) Acromegaly 5 Octreotide 10 nM 150% increase in cleaved cytokeratin
18
Theodoropoulou (23) Acromegaly Octreotide 1–100 nM Increase in Zac1 gene expression
(2006) (GH3 cell
line)
Decrease in PI3K tyrosine
phosphorylation levels
Increase in dephosphorylation Akt and
GSKB
Batista (2006) (61) Cushing’s
disease
6 SOM230 10–70% cell viability reduction
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antiproliferative effects. At the same time, multiple
subtypes may cooperate to induce growth arrest, also in
the light of the recent advances on SSTR biology,
indicating the possibility for these receptors to homo-
and heterodimerize with other G-protein coupled
receptors (27). The availability of SSTR-selective
analogs therefore provides the opportunity to study
the effects of activating single versus multiple SSTRs,
since it now appears that the concept of a single
dominant SSTR subtype controlling a specific biological
function is too simplistic (28).
Trying to elucidatewhichother SSTRmight be involved
in transducing SRIH antiproliferative effects, we investi-
gated SSTR1 activation in pituitary adenomas. For this
purpose, we selected a group of 15 GH-secreting pituitary
adenomas expressing SSTR1 and performed primary
cultures that underwent treatment with SRIH or with a
SSTR1-selective agonist, BIM-23926 at 10 nM. As
expected, we observed a significant inhibition in GH and
PRL secretion not only under SRIH treatment, but also
under treatment with the SSTR1-selective agonist.
Interestingly, this compound was as potent as SRIH ininhibiting pituitary cell viability in vitro. Moreover, we
found a significant positive correlation between the
antiproliferative effects of BIM-23926 on GH and PRL
secretion and SSTR1 mRNA expression. However, such
correlationwas not evident for the antiproliferative effect,
suggesting that even very low SSTR1 expression might
induce the antiproliferative effects of the SSTR1-selective
agonist (29).
These results also indicate that SSTR1 may mediate
SRIH actions at pituitary level, suggesting that this
receptor may represent a target for new therapies
attempting to control growth and hormonal secretion of
pituitary tumors. This hypothesis is further supported by
the finding that a SSTR1-selective agonist significantly
inhibits GH secretion in vitro also in tumors from patients
resistant to octreotide or Lan therapy (30).
The importance of SSTR1 as a possible target for
medical therapy of pituitary adenomas was further
underlined by the study we performed on a selected
group of 12 NFA, all expressing SSTR1, SSTR2 and
SSTR5, as well as chromogranin A (CgA) and
a-subunit. We showed that SSTR1- and SSTR2-selective
agonists inhibit both a-subunit and CgA secretion bywww.eje-online.org
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the SSTR1-selective agonist was capable of significantly
reducing in vitro cell viability, while the SSTR5-selective
agonist enhanced pituitary cell viability. Again, the
inhibitory effects of the SSTR1-selective agonist did not
correlate with the extent of SSTR1 expression, further
supporting the hypothesis that even very low SSTR1
expression might induce the inhibitory effects of the
SSTR1-selective agonist (31). These results suggest that
SRIH analogs with enhanced potency for SSTR1 could
offer useful tools for the medical therapy of NFA. To the
contrary, our results show that the treatment with a
SSTR5-selective agonist significantly promoted NFA cell
viability. This effect might account for the lack of NFA
volume reduction observed in some patients treated
with octreotide or Lan, which mainly interact not only
with SSTR2, but also with SSTR5 (32–35). Moreover,
our findings could explain the increase in tumor volume
observed in some cases during such therapy (33),
suggesting that SSTR5-interacting drugs might fail to
control NFA tumor growth or, on the contrary, might
facilitate pituitary cell survival in these adenomas.
Therefore, the indication for medical therapy with
octreotide or Lan in NFA patients with evidence for
tumor SSTR5 expression should be carefully evaluated.
On the other hand, it has been demonstrated that
growth reduction of the mouse thyrotrope tumor cell
line TtT-97 by thyroid hormone treatment is associated
with increased expression of SSTR5 (36). Further
experiments led to the hypothesis that thyroid hor-
mones, acting through increased SSTR5, could activate
the ERK pathway, resulting in a reduced expression of
critical cell cycle proteins and a subsequent arrest of
S-phase progression. These processes were reversed
upon withdrawal of thyroid hormones, resulting in an
increase in the fraction of S-phase cells (37). In addition,
it has been recently demonstrated that treatment
of dispersed GH-secreting pituitary adenoma cells with
octreotide, as well as pasireotide (SOM230, a novel SRIH
analog interacting with all SSTRs except for SSTR4),
upregulates the expression of a cyclin-dependent
kinase inhibitor, p27, possibly resulting in cell cycle
inhibition (38).
Besides the direct actions on pituitary cells, SRIH and
its analogs also have indirect effects, since they inhibit
production and secretion of many angiogenic factors,
therefore reducing tumor growth rate (39). Neoangio-
genesis is fundamental for tumor growth and one of the
main factors promoting this process is vascular
endothelial growth factor (VEGF). It has been recently
demonstrated that VEGF is overexpressed in the
pituitary of DA receptor subtype 2 (DR2) knockout
mice (40), indicating that this growth factor is under
dopaminergic control. DR2 is extensively expressed in
all pituitary tumor types, as demonstrated by in situ
hybridization and immunohistochemistry (41). It has
also been demonstrated that DR2 knockout mice
develop prolactinomas with age (42, 43), DAwww.eje-online.orgtransporter gene knockout mice show arrested lacto-
trope development (44), and transgenic mice bearing
the short isoform of DR2 (DR2s) display lactotrope
hypoplasia (45). This evidence provides the basis for the
use of DA agonists in the medical treatment of
prolactinomas and highlights the importance of DA
agonists in the control of lactotrope proliferation.
Indeed, it has been recently demonstrated in vivo and
in vitro that lactotrope treatment with DA and its
agonist, bromocriptine, induces transforming growth
factor (TGF)-b1 expression and secretion, which, in
turn, can mediate the antiproliferative effects of DA on
lactotropes. In addition, constitutive expression of the
DR2s receptor upregulated the TGFb1 expression and
action, and inhibited cell proliferation in transformed
lactotropes (46). DR2 activation in lactotropes leads to
the alteration of G-protein coupling, inhibition of
adenylyl cyclase, and reduction of intracellular cAMP
(47, 48). In addition, DRs have been shown to regulate
other transduction pathways that lead to alteration of
intracellular calcium, protein kinase C, and the MAPK
pathway (45, 47–50), resulting in reduced cell
proliferation in a number of cellular models.
However, the effects of DA agonists on pituitary
tumors different from prolactinomas are still a matter of
debate. Indeed, some clinical studies showed that
treatment with DA agonists has no effect on NFA
volume (51), while others documented tumor shrinkage
of up to 11% (52). In vitro studies have shown that,
depending on the dose, bromocriptine is capable of
significantly reducing the cell number in NFA, an effect
reversed by a DR2 antagonist, haloperidol (17). Further
studies showed that DR2 expression is variable in NFA,
and that recurrent tumors lack expression of DR2s (53).
Moreover, three out of nine NFA cultures responded to
bromocriptine in terms of DNA synthesis reduction, and
all responder adenomas expressed DR2s. In all cases,
haloperidol, a DR2-selective antagonist, blocked the
inhibitory effects of bromocriptine, demonstrating that
this action was mediated by DR2. These data suggest
that DR2s expression in NFA favors the growth
suppressive effect of bromocriptine. This hypothesis is
further supported by the finding that DR2s expression is
lower in resistant prolactinomas when compared with
responsive adenomas (54), and that increased DR2s
expression in lactotrope cells results in pituitary
hypoplasia (45). The mechanisms underlying the
antiproliferative effects of DA agonists have been
explored in the GH3 cell line, where the specific
inhibitors of p38 MAPK and ERK pathways completely
abrogated such effect, indicating that DA induces
antiproliferative effects and cell death via DR2, involving
p38 MAPK and ERK pathways (55).
Moreover, it has been recently demonstrated that
approximately 80% of corticotrope pituitary tumors
express functional DR2 and that treatment with
cabergoline is effective in controlling the cortisol
hypersecretion associated with Cushing’s disease (56).






Thapar (1997) (11) Acromegaly 36 Octreotide s.c. (4 months) 83% reduction in growth
fraction
Losa (2001) (12) Acromegaly 39 Octreotide s.c. (12 months) 53% reduction in ki67 labeling
index
Cap (2003) (13) Acromegaly 14 Octreotide (13 pts) and lanreotide
(1 pt; 3 months)
67% reduction in ki67 labeling
index
Bevan (2005) (16) Acromegaly 921 Various compounds and treatment
length
Various extents in tumor size
reduction in 42% of pts
Hubina (2006) (38) Acromegaly 25 Octreotide (12 months) p27 upregulation
Oppizzi (1998) (32) NFA 22 Octreotide No changes in tumor volume
Andersen (2001) (33) NFA 10 Octreotide and cabergoline 30% reduction in tumor
volume in 6 pts
Gasperi (1993) (35) NFA 8 Octreotide s.c. (6 months) No changes in tumor volume
Bevan (1986) (51) NFA 20 Bromocriptine No changes in tumor volume
Liuzzi (1996) (52) NFA n.d. DA agonists 11% reduction in tumor
volume
Pivonello (1999) (56) Nelson’s
syndrome
1 Cabergoline (6 months) Disappearance of pituitary
microadenoma
Illouz (2006) (60) Cushing’s
disease
3 Cabergoline Tumor volume stabilization in
one case
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cabergoline treatment caused remission of Nelson’s
syndrome (57) and normalization of PRL, ACTH, and
cortisol levels in a macroprolactinoma associated with
Cushing’s disease (58), suggesting that the DA agonist
may be useful in restraining hormone secretion by
neoplastic corticotrope cells. In addition, a previous
in vitro study demonstrated that bromocriptine inhibits
murine ACTH-secreting pituitary adenoma (AtT-20)
cell proliferation, likely inducing apoptosis (59), further
supporting the therapeutic use of DA agonists in the
management of Cushing’s disease. And indeed, three
cases of persistent Cushing’s disease have been
described, where treatment with cabergoline induced
a decrease or normalization in hypercortisolism, with
stabilization of tumor volume in one case (60). Besides
the DA agonists, SRIH analogs have been studied as
possible pharmacological agents to treat ACTH-secret-
ing pituitary adenomas. It has been recently demon-
strated that human corticotrope tumors express
multiple SSTR subtypes, and that the multiligand
SRIH analog SOM230 significantly suppresses cell
proliferation, as well as ACTH secretion, in primary
cultures of human corticotrope tumors. These data
suggest that SOM230 may have a role in the medical
therapy of corticotrope tumors (61).
Together with SRIH analogs and DA agonists,
chimeric compounds interacting with SSTR2 or
SSTR5 and DR2 have been explored for their effects
on cell viability. In a recent study, these compounds
were capable of reducing cell viability in most (but not
all) NFA primary cultures, having an inhibitory effect
similar to selective SSTR or DR agonists. However,
bromocriptine was the most effective agonists in
reducing NFA cell viability (62).In conclusion, the antiproliferative effect of SRIH
analogs, DAagonists and chimeras, both in vitro (Table 1)
and in vitro (Table 2), depends on tissue SSTR and DR
expression pattern, the different binding profiles of the
various agonists and SSTR and DR effector coupling.
Further studies are therefore needed to elucidate the
mechanisms underlying such antiproliferative effects
and to verify the possible clinical applications.Acknowledgements
This work was supported by grants from the Italian
Ministry of University and Scientific and Technological
Research (University of Ferrara: 60% – 2006 and MIUR
2005060839-004), Fondazione Cassa di Risparmio di
Ferrara, Associazione Italiana per la Ricerca sul Cancro
(AIRC) and the Associazione Ferrarese dell’Ipertensione
Arteriosa to the University of Ferrara.References
1 Brazeau P & Guillemin R. Somatostatin: newcomer from the
hypothalamus. New England Journal of Medicine 1974 290
963–964.
2 Giustina G, Peracchi M, Reschini E, Panerai AE & Pinto M. Dose–
response study of the inhibiting effect of somatostatin on growth
hormone and insulin secretion in normal subjects and acrome-
galic patients. Metabolism 1975 24 807–815.
3 Hall R, SnowM, ScanlonM,Mora B&Gomez-PanA. Pituitary effects
of somatostatin.Metabolism 1978 27 (Suppl 1) 1257–1262.
4 Culler MD, Taylor JE & Moreau JP. Somatostatin receptor subtypes:
targeting functional and therapeutic specificity. Annals of Endo-
crinology 2002 63 2S5–2S12.www.eje-online.org
S34 M C Zatelli and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007) 1565 Ferjoux G, Bousquet C, Cordelier P, Benali N, Lopez F, Rochaix P,
Buscail L & Susini C. Signal transduction of somatostatin receptors
negatively controlling cell proliferation. Journal of Physiology 2000
94 205–210.
6 Buscail L, Esteve JP, Saint-Laurent N, Bertrand V, Reisine T,
O’Carroll AM, Bell GI, Schally AV, Vaysse N & Susini C. Inhibition
of cell proliferation by the somatostatin analogue RC-160 is
mediated by somatostatin receptor subtypes SSTR2 and SSTR5
through different mechanisms. PNAS 1995 92 1580–1584.
7 Sharma K, Patel YC & Srikant CB. Subtype-selective induction
of wild-type p53 and apoptosis, but not cell cycle arrest, by
human somatostatin receptor 3. Molecular Endocrinology 1996
10 1688–1696.
8 Koper JW, Hofland LJ, van Koetsveld PM, den Holder F &
Lamberts SW. Desensitization and resensitization of rat pituitary
tumor cells in long-term culture to the effects of the somatostatin
analogue SMS 201-995 on cell growth and prolactin secretion.
Cancer Research 1990 50 6238–6242.
9 Hofland LJ, van Koetsveld PM, Wouters N, Waaijers M, Reubi JC &
Lamberts SW. Dissociation of antiproliferative and antihormonal
effects of the somatostatin analog octreotide on 7315b pituitary
tumor cells. Endocrinology 1992 131 571–577.
10 Panetta R & Patel YC. Expression of mRNA for all five human
somatostatin receptors (hSSTR1-5) in pituitary tumors. Life
Sciences 1995 56 333–342.
11 Thapar K, Kovacs KT, Stefaneanu L, Scheithauer BW, Horvath E,
Lloyd RV, Li J & Laws ER Jr. Antiproliferative effect of the
somatostatin analogue octreotide on growth hormone-producing
pituitary tumors: results of a multicenter randomized trial. Mayo
Clinic Proceedings 1997 72 893–900.
12 Losa M, Ciccarelli E, Mortini P, Barzaghi R, Gaia D, Faccani G,
Papotti M, Mangili F, Terreni MR, Camanni F & Giovanelli M.
Effects of octreotide treatment on the proliferation and apoptotic
index of GH-secreting pituitary adenomas. Journal of Clinical
Endocrinology and Metabolism 2001 86 5194–5200.
13 Cap J, Cerman J, Nemecek S, Marekova M, Hana V & Frysak Z. The
influence of treatmentwith somatostatin analogues onmorphology,
proliferative and apoptotic activity in GH-secreting pituitary
adenomas. Journal of Clinical Neurosciences 2003 10 444–448.
14 Ezzat S, Horvath E, Harris AG & Kovacs K. Morphological
effects of octreotide on growth hormone-producing pituitary
adenomas. Journal of Clinical Endocrinology and Metabolism
1994 79 113–118.
15 Bevan JS, Webster J, Burke CW & Scanlon MF. Dopamine
agonists and pituitary tumor shrinkage. Endocrine Reviews
1992 13 220–240.
16 Bevan JS. The antitumoral effects of somatostatin analog therapy
in acromegaly. Journal of Clinical Endocrinology and Metabolism
2005 90 1856–1863.
17 Renner U, Mojto J, Lange M, Muller OA, vonWerder K & Stalla GK.
Effect of bromocriptine and SMS 201-995 on growth of human
somatotrophic and non-functioning pituitary adenoma cells
in vitro. European Journal of Endocrinolology 1994 130 80–91.
18 Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD &
Klibanski A. Somatostatin receptor-specific analogs: effects on cell
proliferation and growth hormone secretion in human somato-
troph tumors. Journal of Clinical Endocrinology and Metabolism
2001 86 2976–2981.
19 Dasgupta P, Singh AT & Mukherjee R. Antiproliferative and
GH-inhibitory activity of chimeric peptides consisting of GHRP-6
and somatostatin. Biochemical Biophysical Research Communi-
cations 1999 259 379–384.
20 Florio T, Thellung S, Corsaro A, Bocca L, Arena S, Pattarozzi A,
Villa V, Massa A, Diana F, Schettini D, Barbieri F, Ravetti JL,
Spaziante R, Giusti M & Schettini G. Characterization of the
intracellular mechanisms mediating somatostatin and lanreotide
inhibition of DNA synthesis and growth hormone release from
dispersed human GH-secreting pituitary adenoma cells in vitro.
Clinical Endocrinology 2003 59 115–128.
21 Ferrante E, Pellegrini C, Bondioni S, Peverelli E, Locatelli M,
Gelmini P, Luciani P, Peri A, Mantovani G, Bosari S, Beck-Peccoz P,www.eje-online.orgSpada A & Lania A. Octreotide promotes apoptosis in human
somatotroph tumor cells by activating somatostatin receptor type
2. Endocrine-Related Cancer 2006 13 955–962.
22 Luciani P, Gelmini S, Ferrante E, Lania A, Benvenuti S, Baglioni S,
Mantovani G, Cellai I, Ammannati F, Spada A, Serio M & Peri A.
Expression of the antiapoptotic gene seladin-1 and octreotide-
induced apoptosis in growth hormone-secreting and nonfunction-
ing pituitary adenomas. Journal of Clinical Endocrinology and
Metabolism 2005 90 6156–6161.
23 Theodoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M,
Erneux C, Florio T, Pagotto U & Stalla GK. Octreotide, a somatostatin
analogue, mediates its antiproliferative action in pituitary tumor
cells by altering phosphatidylinositol 3-kinase signaling and
inducing Zac1 expression. Cancer Research 2006 66 1576–1582.
24 Florio T, Thellung S, Arena S, Corsaro A, Spaziante R, Gussoni G,
Acuto G, Giusti M, Giordano G & Schettini G. Somatostatin and its
analog lanreotide inhibit the proliferation of dispersed human
non-functioning pituitary adenoma cells in vitro. European
Journal of Endocrinology 1999 141 396–408.
25 Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D & Bruns C.
Opportunities in somatostatin research: biological, chemical
and therapeutic aspects. Nature Reviews. Drug Discovery 2003 2
999–1017.
26 Zatelli MC, Piccin D, Tagliati F, Bottoni A, Luchin A & degli
Uberti EC. SHP-1 restrains cell proliferation in human medullary
thyroid carcinoma. Endocrinology 2005 146 2692–2698.
27 Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC & Patel YC.
Receptors for dopamine and somatostatin: formation of hetero-
oligomers with enhanced functional activity. Science 2000 288
154–157.
28 Culler MD. Evolving concepts in the quest for advanced
therapeutic analogues of somatostatin. Digestive and Liver Disease
2004 36 (Suppl 1) S17–S25.
29 Zatelli MC, Piccin D, Tagliati F, Ambrosio MR, Margutti A,
Padovani R, Scanarini M, Culler MD & degli Uberti EC.
Somatostatin receptor subtype 1 selective activation in human
growth hormone- and prolactin-secreting pituitary adenomas:
effects on cell viability, growth hormone and prolactin
secretion. Journal of Clinical Endocrinology and Metabolism
2003 88 2797–2802.
30 Matrone C, Pivonello R, Colao A, Cappabianca P, Cavallo LM, Del
Basso De Caro ML, Taylor JE, Culler MD, Lombardi G, Di Renzo GF &
Annunziato L. Expression and function of somatostatin receptor
subtype 1 in human growth hormone secreting pituitary tumors
deriving from patients partially responsive or resistant to long-term
treatment with somatostatin analogs. Neuroendocrinology 2004 79
142–148.
31 Zatelli MC, Piccin D, Bottoni A, Ambrosio MR, Margutti A,
Padovani R, Scanarini M, Taylor JE, Culler MD, Cavazzini L & degli
Uberti EC. Evidence for differential effects of selective somatostatin
receptor subtype agonists on alpha-subunit and chromogranin A
secretion and on cell viability in human non-functioning pituitary
adenomas in vitro. Journal of Clinical Endocrinology and Metabolism
2004 89 5181–5188.
32 Oppizzi G, Cozzi R, Dallabonzana D, Orlandi P, Benini Z,
Petroncini M, Attanasio R, Milella M, Banfi G & Possa M.
Scintigraphic imaging of pituitary adenomas: an in vivo evaluation
of somatostatin receptors. Journal of Endocrinological Investigation
1998 21 512–519.
33 Andersen M, Bjerre P, Schroder HD, Edal A, Hoilund-Carlsen PF,
Pedersen PH & Hagen C. In vivo secretory potential and the effect of
combination therapy with octreotide and cabergoline in patients
with clinically non-functioning pituitary adenomas. Clinical
Endocrinology 2001 54 23–30.
34 Colao A, Di Sarno A, Marzullo P, Di Somma C, Cerbone G, Landi ML,
Faggiano A, Merola B & Lombardi G. New medical approaches in
pituitary adenomas. Hormone Research 2000 53 (Suppl 3) 76–87.
35 Gasperi M, Petrini L, Pilosu R, Nardi M, Marcello A, Mastio F,
Bartalena L & Martino E. Octreotide treatment does not affect the
size of most non-functioning pituitary adenomas. Journal of
Endocrinological Investigation 1993 16 541–543.
Antiproliferative effects on pituitary adenomas S35EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007) 15636 Wood WM, Sarapura VD, Dowding JM, Woodmansee WW,
Haakinson DJ, Gordon DF & Ridgway EC. Early gene expression
changes preceding thyroid hormone-induced involution of a
thyrotrope tumor. Endocrinology 2002 143 347–359.
37 Woodmansee WW, Kerr JM, Tucker EA, Mitchell JR,
Haakinson DJ, Gordon DF, Ridgway EC & Wood WM. The
proliferative status of thyrotropes is dependent on modulation of
specific cell cycle regulators by thyroid hormone. Endocrinology
2006 147 272–282.
38 Hubina E, Nanzer AM, Hanson MR, Ciccarelli E, Losa M, Gaia D,
Papotti M, Terreni MR, Khalaf S, Jordan S, Czirjak S, Hanzely Z,
Nagy GM, Goth MI, Grossman AB & Korbonits M. Somatostatin
analogues stimulate p27 expression and inhibit the MAP kinase
pathway in pituitary tumours. European Journal of Endocrinology
2006 155 371–379.
39 Barrie R, Woltering EA, Hajarizadeh H, Mueller C, Ure T &
Fletcher WS. Inhibition of angiogenesis by somatostatin and
somatostatin-like compounds is structurally dependent. Journal of
Surgical Research 1993 55 446–450.
40 Cristina C, Diaz-Torga G, Baldi A, Gongora A, Rubinstein M,
Low MJ & Becu-Villalobos D. Increased pituitary vascular
endothelial growth factor-a in dopaminergic D2 receptor knock-
out female mice. Endocrinology 2005 146 2952–2962.
41 Stefaneanu L, Kovacs K, Horvath E, Buchfelder M, Fahlbusch R &
Lancranjan L. Dopamine D2 receptor gene expression in human
adenohypophysial adenomas. Endocrine 2001 14 329–336.
42 Kelly MA, Rubinstein M, Asa SL, Zhang G, Saez C, Bunzow JR,
Allen RG, Hnasko R, Ben-Jonathan N, Grandy DK & Low MJ.
Pituitary lactotroph hyperplasia and chronic hyperprolactine-
mia in dopamine D2 receptor-deficient mice. Neuron 1997 19
103–113.
43 Saiardi A, Bozzi Y, Baik JH & Borrelli E. Antiproliferative role of
dopamine: loss of D2 receptors causes hormonal dysfunction and
pituitary hyperplasia. Neuron 1997 19 115–126.
44 Bosse R, Fumagalli F, Jaber M, Giros B, Gainetdinov RR,
Wetsel WC, Missale C & Caron MG. Anterior pituitary hypoplasia
and dwarfism in mice lacking the dopamine transporter. Neuron
1997 19 127–138.
45 Iaccarino C, Samad TK, Mathis C, Kercret H, Picetti R &
Borrelli E. Control of lactotrope proliferation by dopamine:
essential role of signalling through D2 receptors ERKs. PNAS
2002 99 14530–14535.
46 Sarkar DK, Chaturvedi K, Oomizu S, Boyadjieva NI & Chen CP.
Dopamine, dopamine D2 receptor short isoform, transforming
growth factor (TGF)-beta1, and TGF-beta type II receptor interact
to inhibit the growth of pituitary lactotropes. Endocrinology 2005
146 4179–4188.
47 Enjalbert A & Bockaert J. Pharmacological characterization of
the D2 dopamine receptor negatively coupled with adenylate
cyclase in rat anterior pituitary. Molecular Pharmacology 1983
23 576–584.
48 Martinez de la Escalera G, Guthrie J & Weiner RI. Transient
removal of dopamine potentiates the stimulation of prolactin
release by TRH but not VIP: stimulation via Ca2C/protein kinase
C pathway. Neuroendocrinology 1988 47 38–45.
49 Ben-Jonathan N & Hnasko R. Dopamine as a prolactin (PRL)
inhibitor. Endocrine Reviews 2001 22 724–763.50 Takeuchi Y, Miyamoto E & Fukunaga K. Activation of the rat
dopamine D2 receptor promoter by mitogen-activated protein
kinase and Ca2C/calmodulin-dependent protein kinase II
pathways. Journal of Neurochemistry 2002 83 784–796.
51 Bevan JS & Burke CW. Non-functioning pituitary adenomas do not
regress during bromocriptine therapy but possess membrane-
bound dopamine receptors which bind bromocriptine. Clinical
Endocrinology 1986 25 561–572.
52 Liuzzi A, Tassi V, Pirro MT, Zingrillo M, Ghiggi MR, Chiodini I,
Oppizzi G & Barberis M. Nonfunctioning adenomas of the pituitary.
Metabolism 1996 45 80–82.
53 Renner U, Arzberger T, Pagotto U, Leimgruber S, Uhl E, Muller A,
Lange M, Weindl A & Stalla GK. Heterogeneous dopamine D2
receptor subtype messenger ribonucleic acid expression in
clinically nonfunctioning pituitary adenomas. Journal of Clinical
Endocrinology and Metabolism 1998 83 1368–1375.
54 Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D,
Jaquet P, Kordon C & Enjalbert A. Decreased expression of the two
D2 dopamine receptor isoforms in bromocriptine-resistant
prolactinomas. Neuroendocrinology 1994 60 314–322.
55 An JJ, Cho SR, Jeong DW, Park KW, Ahn YS & Baik JH. Anti-
proliferative effects and cell death mediated by two isoforms of
dopamine D2 receptors in pituitary tumor cells. Molecular and
Cellular Endocrinology 2003 206 49–62.
56 Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML,
Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ &
Lamberts SW. Dopamine receptor expression and function in
corticotroph pituitary tumors. Journal of Clinical Endocrinology and
Metabolism 2004 89 2452–2462.
57 Pivonello R, Faggiano A, Di Salle F, Filippella M, Lombardi G &
Colao A. Complete remission of Nelson’s syndrome after 1-year
treatment with cabergoline. Journal of Endocrinological Investigation
1999 22 860–865.
58 T’Sjoen G, Defeyter I, Van De Saffele J, Rubens R & Vandeweghe M.
Macroprolactinoma associated with Cushing’s disease, success-
fully treated with cabergoline. Journal of Endocrinological Investi-
gation 2002 25 172–175.
59 Yin D, Kondo S, Takeuchi J & Morimura T. Induction of apoptosis
in murine ACTH-secreting pituitary adenoma cells by bromocrip-
tine. FEBS Letters 1994 339 73–75.
60 Illouz F, Dubois-Ginouves S, Laboureau S, Rohmer V & Rodien P.
Use of cabergoline in persisting Cushing’s disease. Annals of
Endocrinology 2006 67 353–356.
61 Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA,
Swearingen B, Hedley-Whyte ET, Stratakis CA & Klibanski A. The
effects of SOM230 on cell proliferation and adrenocorticotropin
secretion in human corticotroph pituitary adenomas. Journal of
Clinical Endocrinology and Metabolism 2006 91 4482–4488.
62 Gruszka A, Kunert-Radek J, Radek A, Pisarek H, Taylor J, Dong JZ,
Culler MD & Pawlikowski M. The effect of selective sst1, sst2, sst5
somatostatin receptors agonists, a somatostatin/dopamine
(SST/DA) chimera and bromocriptine on the “clinically non-
functioning” pituitary adenomas in vitro. Life Sciences 2006 78
689–693.
Received 7 September 2006
Accepted 6 December 2006www.eje-online.org
